Prime Medicine, Inc. sold shares to the Cystic Fibrosis Foundation, with TD Cowen acting as joint book-running manager and filing with the SEC.
2 reports, 1 independent
Updated Aug 2
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Prime Medicine, Inc. sold shares to the Cystic Fibrosis Foundation, with TD Cowen acting as joint book-running manager and filing with the SEC.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Cystic Fibrosis Foundation
non-profit organization in the USA
Nothing else this week.
-
TD Cowen
American investment bank
-
Securities and Exchange Commission (Bangladesh)
government regulatory body overseeing the stock market
Related events
- TD Cowen upgraded Crescent Biopharma shares to 'strong-buy', while Wedbush reiterated 'outperform', and a CEO sold shares under a 10b5-1 plan.
- TD Cowen is managing a share offering for PMV Pharma, which has been filed with the SEC and utilizes Broadridge Financial Solutions for mailing the prospectus.
- TD Cowen provided analyst ratings and price targets for Ardelyx, accompanied by required stock transaction filings with the SEC.
- Leerink partners, TD Cowen, and William Blair initiated coverage and set ratings for Kailera Therapeutics.
Coverage
Newest first; wire copies grouped- GlobeNewswirePrime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc
- GlobeNewswirePrime Medicine Announces Pricing of Public Offering CAMBRIDGE, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new clas